We think big. We’re seeking to transform the way serious diseases are treated. We have drug development programs underway targeting hepatitis C, cystic fibrosis, rheumatoid arthritis, cancer and more. Vertex’s drug discovery platform has been highly productive and is the source of key product opportunities in infectious disease, cystic fibrosis, inflammatory disease, cancer and other areas.

Vertex is a unique place to be and to work. We start our projects believing the impossible can be achieved and we don’t give up easily. We value collaboration, innovation, and scientific excellence above all else. We’re fortunate to have the financial resources to support our research, development and commercial objectives.

Vertex Board members are distinguished by their experience in the area of health care and in high growth business. All of our board members have experience leading major businesses or institutions. All are respected leaders and pioneers in their area of expertise. We think big. We’re seeking to transform the way serious diseases are treated.
Learn more.

Vertex was founded in 1989 and went public in 1991. In 1999, our collaborator GlaxoSmithKline (GSK) launched the first Vertex drug, the HIV protease inhibitor Agenerase (amprenavir). Together with GSK, we subsequently developed a second HIV protease inhibitor, Lexiva (fosamprenavir; marketed outside the U.S. as Telzir). We now have a pipeline of drug candidates targeting infectious disease, cystic fibrosis, inflammatory disease, and cancer. One of our most advanced drugs in development is the oral hepatitis C protease inhibitor telaprevir (VX-950). Vertex now employs more than 1000 people across our major research sites in San Diego, CA, Oxford, U.K. and our headquarters in Cambridge, MA. Vertex was founded in 1989 and went public in 1991. In 1999, our collaborator GlaxoSmithKline (GSK)...
Learn more.

We aim to commercialize breakthrough drugs independently and in collaboration with other companies. Our best known collaborations are with major companies, such as Merck, GlaxoSmithKline, and Johnson & Johnson. But we actually have more than 500 collaborations in place with companies and institutions around the world to tap into scientific and clinical excellence. We think of Vertex as a company that is networked to leverage the power of innovation—with the goal of maximizing the clinical and commercial potential of innovative new drugs. We aim to commercialize breakthrough drugs independently and in collaboration with other companies.
Learn more.